Ampicillin and ceftriaxone for the treatment of Enterococcus faecalis infective endocarditis.

Phase 1

• Conditions: Enterococcus faecalis infectious endocarditis; MedDRA version: 20.0Level: PTClassification code: 10014671Term: Endocarditis enterococcal Class: 100000004862; Therapeutic area: Diseases [C] - Bacterial Infections and Mycoses [C01]; Therapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]

• Registration Number: CTIS2024-511719-40-00
• Lead Sponsor: Fundacion Publica Andaluza Para La Gestion De La Investigacion En Salud De Sevilla

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Study Start: 2024-05-07
• Last Update Posted: 21 August 2024

Recruitment & Eligibility

• Status: ot Recruiting
• Sex: All
• Target Recruitment: 284

Inclusion Criteria

Adult patients (18 years of age or older), Possible or definitive diagnosis of infective endocarditis due to Enterococcus faecalis according to the Duke-ISCVID criteria, Signed informed consent of patients

Exclusion Criteria

Allergy to penicillins or cephalosporins, Pregnancy and lactation, Polymicrobial infection including microorganisms different to E. faecalis

Study & Design

• Study Type: Interventional clinical trial of medicinal product
• Study Design: Not specified